Fosamax and Osteonecrosis of the Jaw: Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Focused Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad context, discussions of pharmaceutical interventions and their potential side effects have been framed for a general audience, emphasizing balanced risk-benefit assessments. As this informational heritage evolves, a more focused examination of specific drug-exposure scenarios becomes necessary. One such area of growing clinical interest involves the relationship between bisphosphonate therapy, particularly Fosamax, and the development of osteonecrosis of the jaw (ONJ). This condition, characterized by exposed necrotic bone in the maxillofacial region, has prompted detailed clinical evidence reviews to better understand causation. The transition from general health discourse to this specialized concern requires careful attention to exposure contexts. While initial discussions centered on patient populations receiving Fosamax for osteoporosis, the scope of inquiry now extends to occupational settings where incidental or chronic exposure may occur. This pivot acknowledges that risk assessment must consider not only therapeutic administration but also potential environmental or workplace-related contact. The shift in focus from broad health education to specific exposure pathways underscores the need for rigorous evaluation of causation evidence, moving beyond general awareness toward targeted risk characterization in diverse contexts.

Bridging General Awareness to Clinical Evidence

Building on the foundational understanding of bisphosphonate therapy and its potential adverse effects, this section transitions to a detailed clinical evidence review of Fosamax (alendronate) and its association with osteonecrosis of the jaw. Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibition of bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate therapy, including Fosamax, is osteonecrosis of the jaw (ONJ).

Clinical Presentation and Risk Factors for ONJ

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves delayed healing after dental procedures, such as tooth extraction or dental implant placement, and may be associated with local infection or spontaneous occurrence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition can develop in patients taking bisphosphonates, including Fosamax, and is generally linked to invasive dental procedures or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone tismedical context provides insights into jawbone-specific responses to bisphosphonate therapy (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates, including alendronate, accumulate in bone and inhibit osteoclast activity, which may impair bone remodeling and repair processes. In the jaw, which undergoes frequent mechanical stress and has a high turnover rate, this suppression of bone turnover can lead to compromised healing, particularly after dental trauma or infection. The resulting avascular necrosis is thought to arise from a combination of reduced bone remodeling, local infection, and impaired vascular supply.

Timeline and Incidence of ONJ with Fosamax Exposure

The timeline between Fosamax exposure and documented ONJ outcomes varies. According to clinical data, the time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a reported adverse event, its incidence in clinical trials for osteoporosis was low and not statistically different from placebo. Nonetheless, post-marketing surveillance has identified cases, and the risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Management and Causation Considerations

For patients who develop severe symptoms, discontinuation of Fosamax is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, although a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The optimal duration of Fosamax use has not been determined, and for low-risk fracture patients, consideration of drug discontinuation after 3 to 5 years is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In safety-communication contexts, the association between Fosamax and ONJ is acknowledged in prescribing information as a warning and precaution. The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that known risk factors should be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation-focused clinical interpretation requires careful evaluation of individual risk factors, including dental history, concomitant medications, and duration of bisphosphonate therapy. While a causal link is supported by mechanistic plausibility and case reports, the low incidence in controlled trials and the presence of confounding factors (e.g., dental procedures, comorbidities) necessitate a nuanced assessment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for treating and preventing osteoporosis, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw. It has been reported in patients taking bisphosphonates like Fosamax, often after invasive dental procedures or local infection. Risk factors include dental surgery, cancer, chemotherapy, corticosteroids, poor oral hygiene, and comorbidities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How common is ONJ in patients taking Fosamax?

In placebo-controlled clinical studies of Fosamax, the incidence of ONJ symptoms was low and similar to placebo. However, post-marketing surveillance has identified cases, and the risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.